C
Concord Biotech Ltd
NSE:CONCORDBIO
Concord Biotech Ltd
NSE:CONCORDBIO
Price:
1 525.5
INR
1.23%
Market Closed
Market Cap:
159.6B
INR
Balance Sheet
Balance Sheet Decomposition
Concord Biotech Ltd
Concord Biotech Ltd
| Current Assets | 9.3B |
| Cash & Short-Term Investments | 3.2B |
| Receivables | 3.4B |
| Other Current Assets | 2.7B |
| Non-Current Assets | 8.3B |
| Long-Term Investments | 95.5m |
| PP&E | 8.1B |
| Intangibles | 7.8m |
| Other Non-Current Assets | 133.3m |
Balance Sheet
Concord Biotech Ltd
Concord Biotech Ltd
Currency: INR
Millions
Annual
| Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
26
|
608
|
889
|
434
|
470
|
|
| Cash Equivalents |
26
|
608
|
889
|
434
|
470
|
|
| Short-Term Investments |
1 982
|
1 411
|
739
|
1 663
|
2 665
|
|
| Total Receivables |
2 113
|
2 153
|
2 420
|
2 933
|
3 789
|
|
| Accounts Receivables |
1 836
|
1 790
|
2 343
|
2 745
|
3 508
|
|
| Other Receivables |
277
|
363
|
77
|
188
|
280
|
|
| Inventory |
1 127
|
1 550
|
1 976
|
2 136
|
2 156
|
|
| Other Current Assets |
139
|
350
|
302
|
111
|
201
|
|
| Total Current Assets |
5 386
|
6 071
|
6 327
|
7 277
|
8 962
|
|
| PP&E Net |
3 809
|
5 577
|
6 436
|
7 655
|
7 865
|
|
| PP&E Gross |
3 809
|
5 577
|
6 436
|
7 655
|
7 865
|
|
| Accumulated Depreciation |
692
|
924
|
1 378
|
1 873
|
2 401
|
|
| Intangible Assets |
1
|
64
|
36
|
2
|
3
|
|
| Note Receivable |
0
|
17
|
36
|
27
|
125
|
|
| Long-Term Investments |
62
|
31
|
28
|
103
|
31
|
|
| Other Long-Term Assets |
147
|
64
|
266
|
76
|
22
|
|
| Total Assets |
9 405
N/A
|
11 825
+26%
|
13 128
+11%
|
15 140
+15%
|
17 007
+12%
|
|
| Liabilities | ||||||
| Accounts Payable |
712
|
464
|
831
|
938
|
944
|
|
| Accrued Liabilities |
0
|
5
|
4
|
3
|
1
|
|
| Short-Term Debt |
0
|
51
|
43
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
136
|
263
|
266
|
251
|
79
|
|
| Other Current Liabilities |
303
|
274
|
408
|
726
|
398
|
|
| Total Current Liabilities |
1 151
|
1 057
|
1 552
|
1 918
|
1 422
|
|
| Long-Term Debt |
385
|
579
|
316
|
64
|
19
|
|
| Deferred Income Tax |
151
|
175
|
210
|
234
|
281
|
|
| Other Liabilities |
16
|
21
|
19
|
23
|
20
|
|
| Total Liabilities |
1 703
N/A
|
1 832
+8%
|
2 096
+14%
|
2 240
+7%
|
1 741
-22%
|
|
| Equity | ||||||
| Common Stock |
95
|
95
|
95
|
105
|
105
|
|
| Retained Earnings |
6 778
|
9 069
|
10 108
|
11 976
|
14 342
|
|
| Additional Paid In Capital |
829
|
829
|
829
|
820
|
820
|
|
| Other Equity |
0
|
0
|
0
|
0
|
15 162
|
|
| Total Equity |
7 702
N/A
|
9 994
+30%
|
11 032
+10%
|
12 900
+17%
|
15 266
+18%
|
|
| Total Liabilities & Equity |
9 405
N/A
|
11 825
+26%
|
13 128
+11%
|
15 140
+15%
|
17 007
+12%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
105
|
105
|
105
|
105
|
105
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
